Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Allogene Therapeutics Inc (ALLO)

Allogene Therapeutics Inc (ALLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 392,087
  • Shares Outstanding, K 209,672
  • Annual Sales, $ 100 K
  • Annual Income, $ -327,270 K
  • EBIT $ -276 M
  • EBITDA $ -268 M
  • 60-Month Beta 0.83
  • Price/Sales 4,061.02
  • Price/Cash Flow N/A
  • Price/Book 0.83

Options Overview Details

View History
  • Implied Volatility 108.03% ( -24.22%)
  • Historical Volatility 79.76%
  • IV Percentile 42%
  • IV Rank 14.77%
  • IV High 678.39% on 05/17/24
  • IV Low 9.15% on 08/15/24
  • Put/Call Vol Ratio 0.01
  • Today's Volume 560
  • Volume Avg (30-Day) 176
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 4,559
  • Open Int (30-Day) 4,203

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.34
  • Number of Estimates 12
  • High Estimate -0.25
  • Low Estimate -0.51
  • Prior Year -0.43
  • Growth Rate Est. (year over year) +20.93%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7800 +5.06%
on 12/20/24
2.7700 -32.49%
on 11/26/24
-0.1800 (-8.78%)
since 11/20/24
3-Month
1.7800 +5.06%
on 12/20/24
3.3599 -44.34%
on 11/07/24
-0.9300 (-33.21%)
since 09/20/24
52-Week
1.7800 +5.06%
on 12/20/24
5.7750 -67.62%
on 03/08/24
-0.9100 (-32.73%)
since 12/20/23

Most Recent Stories

More News
Allogene Therapeutics Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference

Allogene Therapeutics announces CEO David Chang will present at the J.P. Morgan Healthcare Conference on January 15, 2025.Quiver AI SummaryAllogene Therapeutics, Inc., a clinical-stage biotechnology company...

ALLO : 1.8700 (+1.63%)
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ALLO : 1.8700 (+1.63%)
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

ALLO : 1.8700 (+1.63%)
Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock?

Shares of Allogene Therapeutics ALLO have lost nearly 23% year to date, underperforming the industry’s 7.0% decline. The stock has also underperformed the sector and the S&P 500 during the same period,...

ALLO : 1.8700 (+1.63%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
Allogene Therapeutics Announces Participation in December Investor Conferences

ALLO : 1.8700 (+1.63%)
Allogene Therapeutics Announces Promising Preclinical Data for ALLO-329, an AlloCAR Tâ„¢ Therapy Targeting Autoimmune Diseases

ALLO-329 shows promise in treating autoimmune diseases by targeting CD19+ B cells and CD70+ T cells without lymphodepletion.Quiver AI SummaryAllogene Therapeutics has announced promising preclinical data...

ALLO : 1.8700 (+1.63%)
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

ALLO : 1.8700 (+1.63%)
Allogene Therapeutics: Q3 Earnings Snapshot

Allogene Therapeutics: Q3 Earnings Snapshot

ALLO : 1.8700 (+1.63%)
Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

ALLO : 1.8700 (+1.63%)
Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

ALLO : 1.8700 (+1.63%)

Business Summary

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company, primarily focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer.'

See More

Key Turning Points

3rd Resistance Point 2.0900
2nd Resistance Point 2.0100
1st Resistance Point 1.9400
Last Price 1.8700
1st Support Level 1.7900
2nd Support Level 1.7100
3rd Support Level 1.6400

See More

52-Week High 5.7750
Fibonacci 61.8% 4.2489
Fibonacci 50% 3.7775
Fibonacci 38.2% 3.3061
Last Price 1.8700
52-Week Low 1.7800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar